Literature DB >> 8761209

New roles for thalidomide.

R J Powell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8761209      PMCID： PMC2351822          DOI： 10.1136/bmj.313.7054.377

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  10 in total

1.  [Therapeutic experience on the effect of thalidomidomide on lepra reaction].

Authors:  J Sheskin
Journal:  Hautarzt       Date:  1975-01       Impact factor: 0.751

2.  CLINICAL EXPERIENCES WITH THALIDOMIDE IN PATIENTS WITH CANCER.

Authors:  H GRABSTALD; R GOLBEY
Journal:  Clin Pharmacol Ther       Date:  1965 May-Jun       Impact factor: 6.875

3.  Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody.

Authors:  M Youle; J Clarbour; C Farthing; M Connolly; D Hawkins; R Staughton; B Gazzard
Journal:  BMJ       Date:  1989-02-18

4.  Thalidomide promotes metastasis of prostate adenocarcinoma cells (PA-III) in L-W rats.

Authors:  M Pollard
Journal:  Cancer Lett       Date:  1996-03-19       Impact factor: 8.679

5.  Guideline for the clinical use and dispensing of thalidomide.

Authors:  R J Powell; J M Gardner-Medwin
Journal:  Postgrad Med J       Date:  1994-12       Impact factor: 2.401

6.  WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients.

Authors:  C G Iyer; J Languillon; K Ramanujam; G Tarabini-Castellani; J T De las Aguas; L M Bechelli; K Uemura; V Martinez Dominguez; T Sundaresan
Journal:  Bull World Health Organ       Date:  1971       Impact factor: 9.408

7.  Thalidomide for the treatment of chronic graft-versus-host disease.

Authors:  G B Vogelsang; E R Farmer; A D Hess; V Altamonte; W E Beschorner; D A Jabs; R L Corio; L S Levin; O M Colvin; J R Wingard
Journal:  N Engl J Med       Date:  1992-04-16       Impact factor: 91.245

8.  Thalidomide as salvage therapy for chronic graft-versus-host disease.

Authors:  P M Parker; N Chao; A Nademanee; M R O'Donnell; G M Schmidt; D S Snyder; A S Stein; E P Smith; A Molina; D E Stepan; A Kashyap; I Planas; R Spielberger; G Somlo; K Margolin; K Zwingenberger; K Wilsman; R S Negrin; G D Long; J C Niland; K G Blume; S J Forman
Journal:  Blood       Date:  1995-11-01       Impact factor: 22.113

9.  THALIDOMIDE (N-PHTHALOYLGLUTAMIMIDE) IN THE TREATMENT OF ADVANCED CANCER.

Authors:  K B OLSON; T C HALL; J HORTON; C L KHUNG; H F HOSLEY
Journal:  Clin Pharmacol Ther       Date:  1965 May-Jun       Impact factor: 6.875

10.  Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet's disease: use of neurophysiological studies to detect thalidomide neuropathy.

Authors:  J M Gardner-Medwin; N J Smith; R J Powell
Journal:  Ann Rheum Dis       Date:  1994-12       Impact factor: 19.103
  10 in total
  2 in total

1.  Generating hypotheses by discovering implicit associations in the literature: a case report of a search for new potential therapeutic uses for thalidomide.

Authors:  Marc Weeber; Rein Vos; Henny Klein; Lolkje T W De Jong-Van Den Berg; Alan R Aronson; Grietje Molema
Journal:  J Am Med Inform Assoc       Date:  2003-01-28       Impact factor: 4.497

Review 2.  Thalidomide and derivatives: immunological investigations of tumour necrosis factor-alpha (TNF-alpha) inhibition suggest drugs capable of selective gene regulation.

Authors:  S M McHugh; T L Rowland
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.